Microkhim Research and Production Company submitted to the State Expert Center at the Ministry of Health of Ukraine documents for registration of Favipiravir-Microkhim.
“Favipiravir-Microkhim is the first Ukrainian generic of the Japanese antiviral drug Avigan(favipiravir). At the beginning of the year, this drug was included in the domestic protocol for the treatment of the disease caused by COVID-19. At the same time, it is not registered in Ukraine, so it was almost impossible to buy it,” the press service of the company informs.
In September, Japanese researchers in clinical trials received evidence of the effectiveness of the use of “Avigan”(favipiravir)for the treatment of disease caused by coronavirus infection. Previously, this drug has been used successfully during the swine flu epidemic.
It is believed that the drug not only eliminates the clinical manifestations of the disease, but, above all, affects the pathogenesis of the coronavirus in humans. At the same time, back in April in Ukraine, the original drug was included in the list of drugs to prevent the spread of coronavirus disease, which were exempt from import duties and VAT.
In early October 2020, the Cabinet of Ministers of Ukraine approved a draft agreement between the governments of Ukraine and Japan on the transfer of the Favipiravir drug batch as the humanitarian aid for Ukraine.